Erika Yamamoto

Erika Yamamoto

Auto-generated profile, based on publicly available information

Erika Yamamoto

Affiliation Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in The American Journal of Cardiology
Verified
Journal Article
Closed access
KYKo Yamamoto
Ko Yamamoto
MNMasahiro Natsuaki
Masahiro Natsuaki
TMTakeshi Morimoto
Takeshi Morimoto
HSHiroki Shiomi
Hiroki Shiomi
YTYasuaki Takeji
Yasuaki Takeji
TKTakeshi Kimura
Takeshi Kimura

1 March 2021 in The American Journal of Cardiology
Verified
Journal Article
Closed access
KYKo Yamamoto
Ko Yamamoto
MNMasahiro Natsuaki
Masahiro Natsuaki
TMTakeshi Morimoto
Takeshi Morimoto
HSHiroki Shiomi
Hiroki Shiomi
YMYukiko Matsumura-Nakano
Yukiko Matsumura-Nakano
TKTakeshi Kimura
Takeshi Kimura

2 July 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YKYuichi Kawase
Yuichi Kawase
TKTakao Kato
Takao Kato
TMTakeshi Morimoto
Takeshi Morimoto
RHReo Hata
Reo Hata
RMRyosuke Murai
Ryosuke Murai
TKTakeshi Kimura
Takeshi Kimura
Background: Admission systolic blood pressure has emerged as a predictor of postdischarge outcomes of patients with acute decompensated heart failure; however, its validity in varied clinical conditions of this patient subset is unclear. The aim of this study was to further explore the prognostic value of admission systolic blood pressure in patients with acute decompensated heart failure.Methods: The Kyoto Congestive Heart Failure (KCHF) registry is a prospective, observational, multicenter cohort study enrolling consecutive patients with acute decompensated heart failure from 19 participating hospitals in Japan. Clinical characteristics at baseline and prognosis were examined by the following value range of admission systolic blood pressure: <100, 100–139, and ≥140 mmHg. The primary outcome measure was defined as all-cause death after discharge. Subgroup analyses were done for prior hospitalization for heart failure, hypertension, left ventricular ejection fraction, and medications at discharge. We excluded patients with acute coronary syndrome or insufficient data.Results: We analyzed 3564 patients discharged alive out of 3804 patients hospitalized for acute decompensated heart failure. In the entire cohort, lower admission systolic blood pressure was associated with poor outcomes (1-year cumulative incidence of all-cause death: <100 mmHg, 26.8%; 100–139 mmHg, 20.2%; and ≥140 mmHg, 15.1%, p<0.001). The magnitude of the effect of lower admission systolic blood pressure for postdischarge all-cause death was greater in patients with prior hospitalization for heart failure, heart failure with reduced left ventricular ejection fraction, and β-blocker use at discharge than in those without.Conclusions: Admission systolic blood pressure is useful for postdischarge risk stratification in patients with acute decompensated heart failure. Its magnitude of the effect as a prognostic predictor may differ across clinical conditions of patients.

5 May 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EYErika Yamamoto
Erika Yamamoto
TKTakao Kato
Takao Kato
HYHidenori Yaku
Hidenori Yaku
TMTakeshi Morimoto
Takeshi Morimoto
YIYasutaka Inuzuka
Yasutaka Inuzuka
TKTakeshi Kimura
Takeshi Kimura
Objective: The complex link between nutritional status, protein and lipid synthesis, and immunity plays an important prognostic role in patients with heart failure. However, the association between appetite loss at discharge and long-term outcome remains unclear. Methods: The Kyoto Congestive Heart Failure registry is a prospective cohort study that enrolled consecutive patients hospitalized for acute decompensated heart failure (ADHF) in Japan. We assessed 3528 patients alive at discharge, and for whom appetite and follow-up data were available. We compared one-year clinical outcomes in patients with and without appetite loss at discharge. Results: In the multivariable logistic regression analysis using 19 clinical and laboratory factors with P value < 0.1 by univariate analysis, BMI < 22 kg/m2 (odds ratio (OR): 1.57, 95% confidence interval (CI): 1.11–2.24, P = 0.01), CRP >1.0mg/dL (OR: 1.49, 95%CI: 1.04–2.14, P = 0.03), and presence of edema at discharge (OR: 4.30, 95%CI: 2.99–6.22, P<0.001) were associated with an increased risk of appetite loss at discharge, whereas ambulatory status (OR: 0.57, 95%CI: 0.39–0.83, P = 0.004) and the use of ACE-I/ARB (OR: 0.70, 95% CI: 0.50–0.98, P = 0.04) were related to a decreased risk in the presence of appetite loss. The cumulative 1-year incidence of all-cause death (primary outcome measure) was significantly higher in patients with appetite loss than in those without appetite loss (31.0% vs. 15.0%, P<0.001). The excess adjusted risk of appetite loss relative to no appetite loss remained significant for all-cause death (hazard ratio (HR): 1.63, 95%CI: 1.29–2.07, P<0.001). Conclusions: Loss of appetite at discharge was associated with worse 1-year mortality in patients with ADHF. Appetite is a simple, reliable, and useful subjective marker for risk stratification of patients with ADHF.

1 December 2017 in Coronary Artery Disease
Verified
Journal Article
Open access
KBKrzysztof L Bryniarski
Krzysztof L Bryniarski
EYErika Yamamoto
Erika Yamamoto
HTHiguma Takumi
Higuma Takumi
Lei XingLei Xing
Lei Xing
TZThomas Zanchin
Thomas Zanchin
IJIk-Kyung Jang
Ik-Kyung Jang
Cardiovascular mortality of patients with combined peripheral arterial disease (PAD) and coronary artery disease (CAD) is twice as high as that in those with either disease alone. It is known that patients with PAD undergoing percutaneous coronary intervention have a higher incidence of adverse cardiac events such as myocardial infarction or target vessel revascularization. In this study, we compared the detailed characteristics of culprit and nonculprit plaques between patients with and those without PAD using optical coherence tomography. We performed propensity score matching using the following variables: (i) age; (ii) sex; (iii) clinical presentation; (iv) diabetes mellitus; (v) hyperlipidemia; (vi) smoking; (vii) hypertension; (viii) BMI; and (ix) coronary lesion location. Finally, we matched 34 culprit lesions and 30 nonculprit lesions in patients with PAD to 68 culprit lesions and 60 nonculprit lesions in patients without PAD (1 : 2 ratio). In culprit lesions, PAD patients when compared with those without PAD had a higher prevalence of lipid-rich plaque (73.5 vs. 51.5%; P=0.033), higher lipid index (1744±1110 vs. 1246±656; P=0.043), calcification (79.4 vs. 58.8%; P=0.039), macrophage accumulation (70.6 vs. 48.5%; P=0.034), and cholesterol crystals (32.4 vs. 10.3%; P=0.006). In nonculprit lesions, PAD patients had a higher prevalence of calcification (76.7 vs. 55.0%; P=0.046), macrophage accumulation (63.3 vs. 38.3%; P=0.025), and cholesterol crystals (36.7 vs. 16.7%; P=0.034). Our study suggests greater coronary plaque vulnerability in both culprit and nonculprit lesions in patients with PAD. This observation underscores the need for more aggressive risk management in patients with combined PAD and coronary artery disease.

1 July 2010 in Journal of Cardiology
Verified
Journal Article
Closed access
YSYukihito Sato
Yukihito Sato
KNKiyoto Nishi
Kiyoto Nishi
SSSayaka Saijo
Sayaka Saijo
YTYohei Tanada
Yohei Tanada
TGTaisuke Goto
Taisuke Goto
YTYoshiki Takatsu
Yoshiki Takatsu